Finance and markets
After three weeks in court, Mayne Pharma and Cosette Pharmaceuticals await a ruling that could decide their $672m deal’s fate, with FIRB approval still pending.
Most big banks have been poaching talent from each other. ANZ has gone abroad.
The Nuno Matos turnaround story at ANZ is beginning to unfold. The question is whether investors will believe it.
The activist hedge fund has told investors it will push ahead with its effort to spill the Southern Cross board and change its constitution at its annual general meeting next month.
As women leave VC due to limited pathways, Maxine Minter of Co Ventures says there’s another route forward for those who want to stay: building their own funds.
